Quantification of canakinumab in human plasma by liquid chromatography-high resolution mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci
; 1211: 123475, 2022 Nov 15.
Article
en En
| MEDLINE
| ID: mdl-36179539
ABSTRACT
Canakinumab is a fully-human monoclonal immunoglobulin gamma 1 kappa. This interleukin-1ß blocker is used for the treatment of autoinflammatory diseases. Various studies have demonstrated the value of therapeutic drug monitoring of monoclonal antibodies in the management of inflammatory diseases. The purpose of this study was to develop a method to quantify canakinumab plasmatic concentration using liquid chromatography-high-resolution (Orbitrap®) mass spectrometry. The quantification was based on a bottom-up approach with the analysis of one surrogate peptide after an immunopurification of IgG followed by tryptic proteolysis. Rituximab and cetuximab, both IgG1, were tested as internal standards. Chromatographic separation was performed on a bioZenTM Peptide PS-C18 column. Mass detection was conducted in positive ionization mode with Parallel Reaction Monitoring at a resolution of 70,000. The method was fully validated in terms of linearity, sensitivity, selectivity, accuracy and matrix effect. Standards ranged from 2.5 to 75 µg/mL. Intra- and inter-day coefficients of variation ranged from 3.7 to 14.7 %, and accuracy from 97.4 to 104.1 %. This method allowed the determination of canakinumab plasmatic concentrations from eight treated patients. This method is efficient and suitable for routine use in therapeutic drug monitoring or pharmacokinetic studies.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Espectrometría de Masa por Ionización de Electrospray
/
Espectrometría de Masas en Tándem
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article